AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Sana Biotechnology, Inc.

$3.13 -$1.06 (-25.30%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$3.09
Day Range
$3.01$3.17
Year Range
$2.61$6.55
Market Cap
871.05M
AVG Volume
3.42M
Trailing/Forward PE
-4.12/-
PEG ratio
0.3
Dividend Yield
-
Next Earnings Date
2026-11-05
Primary Exchange
NASDAQUS
Net Income (USD) · TTM
-400M-300M-200M-100M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SANA Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-211.82M
26 Q1-241.99M
25 Q4-244.17M
25 Q3-234.41M
25 Q2-252.18M
25 Q1-208.67M
24 Q4-266.76M
24 Q3-305.81M
24 Q2-244.9M
24 Q1-308.61M
Operating Income (USD) · TTM
-400M-300M-200M-100M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SANA Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-208M
26 Q1-237.56M
25 Q4-250.32M
25 Q3-239.99M
25 Q2-258.23M
25 Q1-212.63M
24 Q4-272.72M
24 Q3-312.48M
24 Q2-252.9M
24 Q1-319.81M
EBITDA (USD) · TTM
-300M-200M-100M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SANA EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-200.99M
26 Q1-187.06M
25 Q4-187.98M
25 Q3-175.58M
25 Q2-192.49M
25 Q1-191.38M
24 Q4-249.37M
24 Q3-282.85M
24 Q2-221.5M
24 Q1-284.65M
Cash Flows (USD) · TTM
-300M-200M-100M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SANA Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-135.06M
26 Q1-133.64M
25 Q4-144.77M
25 Q3-158.85M
25 Q2-185.29M
25 Q1-223.9M
24 Q4-256.58M
24 Q3-274.99M
24 Q2-284.86M
24 Q1-273.64M
EPS (USD) · TTM
-2-1.5-1-0.5024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SANA EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-0.75
26 Q1-0.92
25 Q4-0.96
25 Q3-0.97
25 Q2-1.06
25 Q1-0.88
24 Q4-1.16
24 Q3-1.4
24 Q2-1.15
24 Q1-1.53
Expenses (USD) · TTM
0100M200M300M400MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SANA Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q2208.44M
26 Q1191.65M
25 Q4206.65M
25 Q3195.88M
25 Q2218.17M
25 Q1230.35M
24 Q4306.15M
24 Q3359.52M
24 Q2298.08M
24 Q1353.51M
Shares Outstanding (USD) · TTM
-40M-30M-20M-10M010MBuybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SANA Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2-22.82M
26 Q1-24.1M
25 Q4-25.4M
25 Q3-25.5M
25 Q2-30.8M
25 Q1-35.55M
24 Q4-37.68M
24 Q3-39.17M
24 Q2-37.41M
24 Q1-35.87M
Employee Count
020040060020202021202220242025
SANA Employee Count by quarter
PeriodEmployee Count
2025142
2024194
2022421
2021383
2020265
Free Cash Flow Yield
-80%-60%-40%-20%0%med -19.99%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
SANA Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-14.59%
Sep 26-11.87%
Aug 26-11.62%
Aug 26-11.68%
Aug 26-12.87%
Aug 26-13.71%
Jul 26-15.42%
Jul 26-15.18%
Jul 26-15.32%
Jul 26-12.54%
Jul 26-12.04%
Jun 26-14.11%
Jun 26-15.32%
Jun 26-18.01%
Jun 26-18.01%
May 26-14.63%
May 26-15.72%
May 26-15.72%
May 26-16.29%
May 26-17.48%
Apr 26-17.38%
Apr 26-16.24%
Apr 26-18.5%
Apr 26-17.86%
Mar 26-20.64%
Mar 26-18.38%
Mar 26-17.01%
Mar 26-18.15%
Feb 26-14.48%
Feb 26-15.21%
Feb 26-15.84%
Feb 26-15.52%
Jan 26-13.77%
Jan 26-12.63%
Jan 26-13.31%
Jan 26-13.37%
Jan 26-14.55%
Dec 25-13.83%
Dec 25-13.99%
Dec 25-11.86%
Dec 25-11.89%
Nov 25-14.18%
Nov 25-18.53%
Nov 25-15.28%
Nov 25-14.91%
Oct 25-15.7%
Oct 25-13.9%
Oct 25-15.45%
Oct 25-17.99%
Oct 25-19.63%
Sep 25-23.27%
Sep 25-25.15%
Sep 25-24.14%
Sep 25-26.26%
Aug 25-25.4%
Aug 25-21.71%
Aug 25-23.34%
Aug 25-31.41%
Aug 25-24.1%
Jul 25-19.04%
Jul 25-20.35%
Jul 25-22.55%
Jul 25-29.54%
Jun 25-33.54%
Jun 25-36.11%
Jun 25-36.39%
Jun 25-33.18%
May 25-43.43%
May 25-47.36%
May 25-53.85%
May 25-51.78%
May 25-57.45%
Apr 25-61.35%
Apr 25-65.81%
Apr 25-61.7%
Apr 25-73.37%
Mar 25-63.5%
Mar 25-47.01%
Mar 25-39.87%
Mar 25-45.28%
Feb 25-44.76%
Feb 25-38.81%
Feb 25-36.97%
Feb 25-39.07%
Jan 25-36.28%
Jan 25-34.56%
Jan 25-36.97%
Jan 25-31.92%
Jan 25-68.31%
Dec 24-72.55%
Dec 24-70.8%
Dec 24-61.81%
Dec 24-50.79%
Nov 24-42.02%
Nov 24-44.76%
Nov 24-48.27%
Nov 24-38.81%
Nov 24-33.2%
Oct 24-32.32%
Oct 24-28.73%
Price to Book
02.557.51012.5med 5.21Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
SANA Price to Book by quarter
PeriodPrice to Book
Sep 265.99
Sep 267.36
Aug 267.52
Aug 267.48
Aug 266.79
Aug 268.17
Jul 267.27
Jul 267.38
Jul 267.31
Jul 268.94
Jul 269.31
Jun 267.94
Jun 267.31
Jun 266.22
Jun 266.22
May 267.66
May 267.13
May 267.13
May 265.52
May 265.15
Apr 265.18
Apr 265.54
Apr 264.86
Apr 265.04
Mar 264.36
Mar 264.9
Mar 265.29
Mar 264.96
Feb 265.62
Feb 265.35
Feb 265.13
Feb 265.24
Jan 265.91
Jan 266.44
Jan 266.11
Jan 266.08
Jan 265.59
Dec 255.88
Dec 255.82
Dec 256.86
Dec 256.84
Nov 255.74
Nov 254.39
Nov 255.32
Nov 255.46
Oct 259.63
Oct 2510.87
Oct 259.78
Oct 258.4
Oct 257.7
Sep 256.5
Sep 256.01
Sep 256.26
Sep 255.76
Aug 255.95
Aug 256.96
Aug 256.48
Aug 253.41
Aug 254.44
Jul 255.62
Jul 255.26
Jul 254.75
Jul 253.62
Jun 253.19
Jun 252.97
Jun 252.94
Jun 253.23
May 252.47
May 252.26
May 251.99
May 252.07
May 251.78
Apr 251.67
Apr 251.56
Apr 251.66
Apr 251.4
Mar 251.61
Mar 252.18
Mar 252.36
Mar 252.08
Feb 252.1
Feb 252.42
Feb 252.54
Feb 252.41
Jan 252.59
Jan 252.72
Jan 252.54
Jan 252.95
Jan 251.38
Dec 241.3
Dec 241.33
Dec 241.52
Dec 241.85
Nov 242.24
Nov 242.1
Nov 241.95
Nov 242.42
Nov 242.53
Oct 242.6
Oct 242.92
Sana Biotechnology, Inc.
SANA
Stockpicker

Video analysis: SANA

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: SANA

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

seekingalpha.com · 10 Sep 2026

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

seekingalpha.com · 10 Sep 2026

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

prnewswire.com · 7 Sep 2026

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Sana Biotechnology to Present at September 2026 Investor Conferences

globenewswire.com · 1 Sep 2026

Sana Biotechnology to Present at September 2026 Investor Conferences

SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update.

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $9.50 Consensus PT from Brokerages

defenseworld.net · 30 Jul 2026

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $9.50 Consensus PT from Brokerages

Sana Biotechnology, Inc. (NASDAQ: SANA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

prnewswire.com · 29 Jul 2026

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

zacks.com · 20 Jul 2026

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.

Sana (SANA) Upgraded to Buy: Here's What You Should Know

zacks.com · 15 Jul 2026

Sana (SANA) Upgraded to Buy: Here's What You Should Know

Sana (SANA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.